Literature DB >> 19147622

Unchanged incidence of microalbuminuria in children with type 1 diabetes since 1986: a UK based inception cohort.

R Amin1, B Widmer, R N Dalton, D B Dunger.   

Abstract

AIMS: To prospectively determine the change in prevalence of microalbuminuria in relation to changes in glycaemic control in children diagnosed with type 1 diabetes between 1986 and 1996.
DESIGN: Prospective observational study of an inception cohort.
SETTING: The geographically defined region of Oxfordshire, UK. PATIENTS: 527 children diagnosed with type 1 diabetes under 16 years of age, were divided into three groups based on year of diagnosis of diabetes: group A (1986-1989, n = 165), group B (1990-1993, n = 179) and group C (1994-1996, n = 183). Each group was followed prospectively for 10 years. MAIN OUTCOME MEASURES: Cumulative prevalence of microalbuminuria.
RESULTS: After 4052 patient years of follow-up, in groups C versus B versus A, the cumulative prevalence of microalbuminuria was 31.7% (95% CI 20.9 to 42.5), 24.8% (17.8 to 31.8) and 23.2% (15.4 to 30.0) (log rank p = 0.22), and risk for development of microalbuminuria was not associated with year of onset of diabetes (hazard ratio 1.05 (0.99 to 1.12), p = 0.11). In groups C versus B versus A, glycaemic control improved after 10 years of diabetes (mean HbA1c 8.9% (1.5%) vs 9.4% (1.5%) vs 10.1% (1.7%), p value for ANOVA <0.001) and more children achieved an HbA1c level <7.5% (15.6% vs 5.9% vs 6.1%, p value for ANOVA = 0.032).
CONCLUSION: In this UK based inception cohort of children diagnosed with type 1 diabetes, the adjusted prevalence of microalbuminuria was unchanged since 1986, despite some improvements in glycaemic control. This observation highlights the need for more proactive intervention with drugs such as angiotensin converting enzyme (ACE) inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147622     DOI: 10.1136/adc.2008.144337

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  7 in total

Review 1.  Microvascular disease in children and adolescents with type 1 diabetes and obesity.

Authors:  M Loredana Marcovecchio; Francesco Chiarelli
Journal:  Pediatr Nephrol       Date:  2010-08-19       Impact factor: 3.714

Review 2.  When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes.

Authors:  Kevin V Lemley
Journal:  Pediatr Nephrol       Date:  2010-03-30       Impact factor: 3.714

Review 3.  Long-term Outcomes in Youths with Diabetes Mellitus.

Authors:  Neil H White
Journal:  Pediatr Clin North Am       Date:  2015-05-23       Impact factor: 3.278

4.  Continued reduction in the prevalence of retinopathy in adolescents with type 1 diabetes: role of insulin therapy and glycemic control.

Authors:  Elizabeth Downie; Maria E Craig; Stephen Hing; Janine Cusumano; Albert K F Chan; Kim C Donaghue
Journal:  Diabetes Care       Date:  2011-11       Impact factor: 19.112

5.  Estrogen receptor α gene polymorphism and vascular complications in girls with type 1 diabetes mellitus.

Authors:  Bartosz Słomiński; Jolanta Myśliwska; Monika Ryba-Stanisławowska; Maria Skrzypkowska; Małgorzata Myśliwiec
Journal:  Mol Cell Biochem       Date:  2017-06-20       Impact factor: 3.396

6.  Dietary Patterns Over Time and Microalbuminuria in Youth and Young Adults With Type 1 Diabetes: The SEARCH Nutrition Ancillary Study.

Authors:  Tina Costacou; Jamie Crandell; Anna R Kahkoska; Angela D Liese; Dana Dabelea; Jean M Lawrence; David J Pettitt; Kristi Reynolds; Elizabeth J Mayer-Davis; Amy K Mottl
Journal:  Diabetes Care       Date:  2018-06-14       Impact factor: 19.112

7.  Factors associated with microalbuminuria in 7,549 children and adolescents with type 1 diabetes in the T1D Exchange clinic registry.

Authors:  Mark Daniels; Stephanie N DuBose; David M Maahs; Roy W Beck; Larry A Fox; Rose Gubitosi-Klug; Lori M Laffel; Kellee M Miller; Heather Speer; William V Tamborlane; Michael J Tansey
Journal:  Diabetes Care       Date:  2013-04-22       Impact factor: 19.112

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.